Journal Information
Vol. 12. Issue 2.
Pages 53-57 (April - June 1976)
Share
Share
Download PDF
More article options
Vol. 12. Issue 2.
Pages 53-57 (April - June 1976)
Full text access
Aspectos inmunologicos de los carcinomas broncopulmonares: Correlacion con el estadio tumoral, respuesta a la terapeutica y supervivencia
Inmunological aspects of bronchopulmonary carcinomas. Correlation with the tumor stage, response to therapy and survival rate
Visits
2787
E. Simó-Camps*, F. Manresa**, A. Anguera*, J.M.a Vich*, E. Batlló***, G. Vidal**, J.M.a Puigdollers***, G. Manresa-Formosa**
* Departamento de Inmunología y Quimioterapia Antitumoral. Universidad Autónoma de Barcelona. Hospital Sagrado Corazón
** Instituto de Neumología Clínica Ntra. Sra. de la Merced. Barcelona
*** Hospital del Sagrado Corazón. Barcelona
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Resumen

La inmunidad celular fue estudiada en 79 pacientes afectos de carcinoma de pulmón, 50 testigos sanos y 14 tumoraciones benignas, observando si existía relación entre el estudio inmunológico de los pacientes y el estadio clínico de la enfermedad. La hipersensibilidad retardada fue correlacionada con el tipo histológico tumoral, el estadio de la enfermedad, la respuesta a la quimioterapia, el pronóstico y la supervivencia. Pacientes con anergia presentaban tumores muy diferenciados, falta de respuesta a la terapéutica, avanzada enfermedad y escasa supervivencia. En los pacientes con buena respuesta inmune, la enfermedad se hallaba limitada, respondían más frecuentemente a la terapéutica y presentaban una mayor supervivencia

Summary

Cellular immunity was studied in 79 patients with carcinoma of the lung, 50 healthy individuals, and 14 cases with bening tumors, to see if there was any relationship between the immunological study of the patients and the clinical stage of the disease. The delayed hypersensitivity was related to the histological tumor type, the stage of the disease, response to chemotherapy, prognosis and survival rate. Anergic patients showed well differentiated tumors, lack of response to therapy, advanced disease, and low survival rate. In patients with good immune response the disease was limited, there was more frequent response to therapy and they displayed a higher survival rate.

Full text is only aviable in PDF
Bibliografia
[1.]
A.C. Aisenberg.
Manifestations of immunologic unresponsivenes in Hodhkin's disease.
Cancer Res., 26 (1966), pp. 1.152
[2.]
R.S. Brown, H.A. Haynes, T. Foley, H.A. Godwin, C.W. Bernard, P.P. Carbone.
Hodgkin's disease: Immunologic, clinical and histologic features of fifty untreated patients.
Ann. Intern. Med., 67 (1967), pp. 291
[3.]
L. Cone, J.W. Uhr.
Immunologic deficiency disorders associated with chronic lymphocyte leukemia and múltiple myeloma.
J Clin. Invest., 43 (1964), pp. 2.241
[4.]
A.R. Cheema, E.M. Hers.
Patient survival after chemotherapy and its relationship to in vitro lymphocyte blastogenesis.
Cancer, 28 (1971), pp. 851
[5.]
F.R. Eilber, D.L. Morton.
Impaired immunologic reactivity and recurrence following cancer surgery.
Cancer, 25 (1970), pp. 362
[6.]
M.J. Krant, G. Manskopf, C.S. Branddrup, M.A. Madoff.
Immunologic alterations in bronchogenic cancer.
Cancer, 21 (1968), pp. 623
[7.]
L. Israel, A. Bouvrain, J. Crosdecam, J. Mugica.
Contribution a l’etude des phenomenes d’immunité cellulaire chez les cancereux pulmonaires. Avant traiæment palliacif ou chirurgical.
Poumon et Coeur, 24 (1968), pp. 339
[8.]
J. Ducos, J. Migueres, P. Colombies, A. Kessous, N. Poujoulet.
Lymphocyte response to PHA in patiens with lung cancer.
[9.]
Brugarolas, A. y Takita, H.: Skin test in the stating of carcinoma of the lung. Clin. Res., 19: 737, 1071
[10.]
T. Han, H. Takita.
Immunologic impairment in bronchogenic carcinoma: a study of lymphocytes response to phytohemagglutinin.
Cancer, 30 (1972), pp. 616
[11.]
A. Brugarolas, H. Takita.
Immunologic status in lung cancer.
Chest, 64 (1973), pp. 427
[12.]
S.A. Wells, J.F. Burdick, W.L. Joseph, C.L. Christiansen, W.G. Wolfe, P.C. Adkins.
Delayed cutaneous hypersensitivity reactins to tumot cell antigens and to nonspecific antigens. Prognostic significance in patiens with lung cancer.
J. Thorac. Cardiovasc. Surg., 66 (1973), pp. 557
[13.]
W.J. Catalona, P.T. Taylor, A.S. Rabson, P.B. Chretien.
A method for D.N.C.B. contad sensitization: A clinicopathologic study.
New. Engl. J. Med., 286 (1972), pp. 399
[14.]
J.M. Moragas, A. Anguera.
Indice de transformación blastica de los linfocitos en las farmacodermias.
Rev. Clin. Esp., 124 (1972), pp. 3
[15.]
M. Soborg, G. Bendixen.
Human lymphocyte migration as a parameter of hypersensitivity.
Acta Med., Scand., 181 (1967), pp. 247
[16.]
G. Mancini, A.D. Carbonova, J.F. Heremans.
Immunochemical quan-titation of antigens by single radial inmunodiffusion.
Immunochemistry., 2 (1965), pp. 235
[17.]
C. Mountain.
Prognestic implications of presurgical stating in lung cancer.
cancer Medicine (Holland), pp. 1.491-1.492
[18.]
D.L. Morton, E.C. Holmes, R.F. Eilber, W.C. Wood.
Immunological aspects of neoplasia: A rational basis for immunotherapy.
Ann. Intern. Med., 74 (1971), pp. 587
[19.]
R.C. Chakravotty, P. Curutchet, F.S. Copolla, Ch.M. Park, K. Blayloch, W. Lawrence Jr..
The delayed hypersensitivity reaction in the cancer patients: Observations on sensitization by D.N.
C.B. Sugery, 73 (1973), pp. 730
[20.]
W.j Catalona, P.B. Chretien.
Abnormalities of quantitative Dinitrochlorobenzene sensitization in cancer patients: Correlation with tumor stage and histology.
Cancer, 31 (1973), pp. 353
[21.]
E.M. Hers, J.J. Oppenheim.
Impaired In Vitro lymphocyte transformation in Hodgkin's disease.
New. Engl. J. Med., 273 (1965), pp. 1.003,
[22.]
H.S. Nelson.
Delayed hypersensitivity in cancer patients. Cutaneous and in vitro lymphocyte response to specific antigens.
Natl. Cancer Inst., 42 (1969), pp. 765
[23.]
P.L. Twomey, W.J. Catalona, P.B. Chretien.
Cellular immunty in cured cáncer patients.
Cancer, 33 (1974), pp. 435
Copyright © 1976. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?